US · KYNB
Kyntra Bio, Inc.
- Sector
- Healthcare · Medical - Pharmaceuticals
- Headquarters
- San Francisco, CA 94133
- Website
- kyntrabio.com
Price · as of 2024-12-31
$7.09
Market cap 28.03M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.93 | +322.14% |
| Intrinsic Value(DCF) | $3.71 | -47.67% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $12.87 | +81.58% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | $0.11 | $0.00 | |||
| 2014 | $703.25 | $306.03 | $35.81 | $0.00 | $0.00 |
| 2015 | $465.00 | $228.20 | $72.10 | $0.00 | $0.00 |
| 2016 | $646.25 | $294.27 | $0.68 | $0.00 | $0.00 |
| 2017 | $1,386.25 | $778.00 | $5.08 | $0.00 | $35.56 |
| 2018 | $1,359.25 | $571.06 | $27.00 | $0.92 | $0.00 |
| 2019 | $992.75 | $420.51 | $46.01 | $1.51 | $0.00 |
| 2020 | $878.75 | $390.20 | $1.86 | $0.00 | $45.74 |
| 2021 | $321.25 | $154.44 | $0.00 | $0.00 | $0.00 |
| 2022 | $503.00 | $221.10 | $0.00 | $0.00 | $95.15 |
| 2023 | $45.00 | $38.71 | $0.00 | $0.00 | $162.90 |
| 2024 | $9.27 | $29.93 | $0.00 | $0.00 | $12.87 |
AI valuation
Our deep-learning model estimates Kyntra Bio, Inc.'s (KYNB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.93
- Current price
- $7.09
- AI upside
- +322.14%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.71
-47.67% upside
Graham-Dodd
—
— upside
Graham Formula
$12.87
+81.58% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| KYNB | Kyntra Bio, Inc. | $7.09 | 28.03M | +322% | -48% | — | +82% | -19.50 | -4.11 | 31.33 | -6.79 | — | -4.11 | 47.47% | -507.80% | -160.63% | 22.14% | 65.97% | -14.91% | -0.40 | -18.24 | 1.47 | 0.38 | -0.28 | -8356.00% | -3671.00% | -5646.00% | -14.90% | -1.04 | 60.75% | 0.24% | -4.70% | 2.08% | -6.43 | -7.00 | 32.67 | -12.75 |
| ALGS | Aligos Therapeutics, Inc. | $7.03 | 43.26M | -26% | -26% | — | +18,737% | -0.62 | -2.80 | 20.55 | -0.38 | -0.12 | -2.80 | 100.00% | -2259.92% | -3326.01% | -415.84% | 162.06% | -118.41% | -0.29 | — | 2.86 | 2.62 | 0.33 | 49489.00% | -7460.00% | 235.00% | -99.76% | -3.71 | 147.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 8.24 | -15.30 |
| CELU | Celularity Inc. | $1.23 | 29.59M | +3,881% | -60% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| KZR | Kezar Life Sciences, Inc. | $6.70 | 49.07M | +394% | — | — | — | -5.31 | 3.80 | — | -4.05 | — | 3.80 | 0.00% | — | — | -55.00% | -3029.25% | -45.77% | 0.14 | -56.88 | 6.76 | 6.53 | 0.32 | -1786.00% | -10000.00% | -1104.00% | -16.69% | -3.65 | -2482.15% | 0.00% | 0.00% | 2.03% | -3.63 | -4.43 | — | 4.31 |
| MRSN | Mersana Therapeutics, Inc… | $29.08 | 145.36M | +85% | +9,159% | — | — | -0.96 | -7.01 | 1.65 | 0.62 | — | -7.01 | 95.98% | -181.09% | -170.86% | -505.14% | 57.77% | -37.33% | -3.01 | -18.93 | 2.19 | 2.16 | 1.25 | -6180.00% | 988.00% | -5178.00% | -123.65% | -1.32 | 64.97% | 0.00% | 0.00% | 0.00% | 0.54 | 0.48 | -0.97 | -9.18 |
| OKUR | OnKure Therapeutics, Inc. | $2.71 | 36.72M | — | — | — | — | -1.27 | 0.64 | — | 0.83 | -2.59 | 0.64 | 0.00% | — | — | -5304.43% | 79.46% | -69.93% | 0.01 | -181.29 | 10.73 | 10.52 | 2.12 | 4906.00% | — | 4707.00% | -76.41% | -4.85 | 74.76% | 0.00% | 0.00% | 120.18% | 0.79 | 0.83 | — | 1.25 |
| PDSB | PDS Biotechnology Corpora… | $0.68 | 36.94M | — | — | — | — | -1.19 | 2.36 | — | -0.74 | — | 2.36 | 0.00% | — | — | -166.65% | 954.97% | -71.81% | 1.15 | -7.77 | 2.64 | 2.44 | 0.59 | -2590.00% | — | 423.00% | -78.19% | -2.05 | 943.09% | 0.00% | 0.00% | 0.00% | -0.69 | -0.71 | — | -6.50 |
| TPST | Tempest Therapeutics, Inc… | $2.28 | 11.23M | — | — | — | — | -7.25 | 15.85 | — | -7.18 | — | 15.85 | 0.00% | — | — | -182.35% | -676.64% | -89.90% | 0.80 | -31.93 | 2.21 | 2.13 | 0.37 | -2147.00% | — | 2156.00% | -11.03% | -2.32 | -538.75% | 0.00% | 0.00% | 0.00% | -6.86 | -8.62 | — | -1.70 |
| XFOR | X4 Pharmaceuticals, Inc. | $3.44 | 39.24M | — | +23% | — | — | -1.89 | 3.20 | 27.68 | -1.70 | — | -13.60 | 68.83% | -1423.58% | -1464.61% | -102.26% | 1092.96% | -25.50% | 3.53 | -4.15 | 3.41 | 3.16 | -0.81 | -6731.00% | — | 3589.00% | -185.42% | -3.98 | 3940.16% | 0.00% | 0.00% | 0.00% | -1.29 | -0.36 | 18.30 | -4.74 |
| XLO | Xilio Therapeutics, Inc. | $0.53 | 27.74M | — | — | — | — | -0.84 | 2.76 | 7.67 | -0.03 | — | 2.76 | 100.00% | -954.95% | -918.05% | -214.02% | 466.54% | -88.24% | 0.46 | -605.82 | 2.21 | 2.03 | 0.81 | -6079.00% | — | -7335.00% | -37.86% | -0.67 | 141.80% | 0.00% | 0.00% | 28.58% | -0.02 | -0.08 | 0.24 | -9.18 |
About Kyntra Bio, Inc.
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
- CEO
- Thane Wettig
- Employees
- 225
- Beta
- 0.83
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.71 ÷ $7.09) − 1 = -47.67% (DCF, example).